HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport

References

• Gotink KJ, Broxterman HJ, Honeywell RJ, et al. Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience. 2014;1:844–853.
   PubMedGoogle Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884–896.
   PubMed Web of Science ®Google Scholar
• Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29:653–668.
   PubMed Web of Science ®Google Scholar
• DeVorkin L, Hattersley M, Kim P, et al. Autophagy inhibition enhances sunitinib efficacy in clear cell ovarian carcinoma. Mol Cancer Res. 2017;15:250–258.
   PubMed Web of Science ®Google Scholar
• Wiedmer T, Blank A, Pantasis S, et al. Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism. Mol Cancer Ther. 2017;16:2502–2515.
   PubMed Web of Science ®Google Scholar
• Melnyk N, Xie XQ, Koh DJY, et al. CTEP #8342 autophagy modulation with antiangiogenic therapy: A phase I trial of sunitinib (Su) and hydroxychloroquine (HCQ). J Clin Oncol. 2013;31.
   Web of Science ®Google Scholar
• Cabrera S, Maciel M, Herrera I, et al. Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis. Autophagy. 2015;11:670–684.
   PubMed Web of Science ®Google Scholar
• Bradner JE. Cancer: an essential passenger with p53. Nature. 2015;520:626–627.
   PubMed Web of Science ®Google Scholar
• Allen MA, Andrysik Z, Dengler VL, et al. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. ELife. 2014;3:e02200.
   PubMed Web of Science ®Google Scholar
• Bieging KT, Attardi LD. Cancer: A piece of the p53 puzzle. Nature. 2015;520:37–38.
   PubMed Web of Science ®Google Scholar
• Hessa T, Sharma A, Mariappan M, et al. Protein targeting and degradation are coupled for elimination of mislocalized proteins. Nature. 2011;475:394–397.
   PubMed Web of Science ®Google Scholar
• Wang C, Ge Q, Zhang Q, et al. Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis. J Exp Clin Cancer Res. 2016;35:53.
   PubMed Web of Science ®Google Scholar
• Lu K, Psakhye I, Jentsch S. A new class of ubiquitin-Atg8 receptors involved in selective autophagy and polyQ protein clearance. Autophagy. 2014;10:2381–2382.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Wang XL, et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 2014;21:1792–1804.
   PubMed Web of Science ®Google Scholar
• Coffill CR, Lee AP, Siau JW, et al. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans. Genes Dev. 2016;30:281–292.
   PubMed Web of Science ®Google Scholar
• Munoz-Braceras S, Calvo R, Escalante R. TipC and the chorea-acanthocytosis protein VPS13A regulate autophagy in Dictyostelium and human HeLa cells. Autophagy. 2015;11:918–927.
   PubMed Web of Science ®Google Scholar
• Gomez-Puerto MC, Folkerts H, Wierenga AT, et al. Autophagy proteins ATG5 and ATG7 are essential for the maintenance of human CD34+ hematopoietic stem-progenitor cells. Stem Cells. 2016;34:1651–1663.
   PubMed Web of Science ®Google Scholar
• Peng Y, Puglielli L. Nε-lysine acetylation in the lumen of the endoplasmic reticulum: A way to regulate autophagy and maintain protein homeostasis in the secretory pathway. Autophagy. 2016;12:1051–1052.
   PubMed Web of Science ®Google Scholar
• An WG, Kanekal M, Simon MC, et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature. 1998;392:405–408.
   PubMed Web of Science ®Google Scholar
• Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000;2:569–573.
   PubMed Web of Science ®Google Scholar
• Ding WX, Ni HM, Gao W, et al. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem. 2007;282:4702–4710.
   PubMed Web of Science ®Google Scholar
• Qu L, Huang S, Baltzis D, et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev. 2004;18:261–277.
   PubMed Web of Science ®Google Scholar
• Ogata M, Hino SI, Saito A, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol. 2006;26:9220–9231.
   PubMed Web of Science ®Google Scholar
• Smart P, Lane EB, Lane DP, et al. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene. 1999;18:7378–7386.
   PubMed Web of Science ®Google Scholar
• Livesey KM, Kang R, Vernon P, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 2012;72:1996–2005.
   PubMed Web of Science ®Google Scholar
• Yang L, Xie M, Yang M, et al. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun. 2014;5:4436.
   PubMed Web of Science ®Google Scholar
• Hua F, Li K, Yu JJ, et al. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat Commun. 2015;6:7951.
   PubMed Web of Science ®Google Scholar
• Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282:24131–24145.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Enot D, Senovilla L, et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;12:864–875.
   PubMed Web of Science ®Google Scholar
• Mross K, Scheulen M, Strumberg D, et al. FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases–a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. Int J Clin Pharmacol Ther. 2014;52:642–652.
   PubMed Web of Science ®Google Scholar
• Vakifahmetoglu-Norberg H, Kim M, Xia HG, et al. Chaperone-mediated autophagy degrades mutant p53. Genes Dev. 2013;27:1718–1730.
   PubMed Web of Science ®Google Scholar
• Rodriguez OC, Choudhury S, Kolukula V, et al. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012;11:4436–4446.
   PubMed Web of Science ®Google Scholar
• Choudhury S, Kolukula VK, Preet A, et al. Dissecting the pathways that destabilize mutant p53 The proteasome or autophagy? Cell Cycle. 2013;12:1022–1029.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Saxena R, Sinclair E, et al. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ. 2016;23:1615–1627.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Oikawa T, Hashimoto S, et al. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. J Cell Biol. 2016;213:81–95.
   PubMed Web of Science ®Google Scholar
• Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014;4:405–414.
   PubMed Web of Science ®Google Scholar
• Nakashima N, Kuwano K, Maeyama T, et al. The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. J Clin Pathol. 2005;58:583–589.
   PubMed Web of Science ®Google Scholar
• Kurinna S, Stratton SA, Coban Z, et al. p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology. 2013;57:2004–2013.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Sakata Y, Suna S, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res. 2013;113:322–326.
   PubMed Web of Science ®Google Scholar
• Sun X, Tang D. HMGB1-dependent and -independent autophagy. Autophagy. 2014;10:1873–1876.
   PubMed Web of Science ®Google Scholar
• Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. 2014;141:347–357.
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Cheh CW, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010;29:5299–5310.
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Pham LDD, Katusic ZS, et al. Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc Natl Acad Sci U S A. 2012;109:7505–7510.
   PubMed Web of Science ®Google Scholar
• Awuah SG, Riddell IA, Lippard SJ. Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity. Proc Natl Acad Sci U S A. 2017;114:950–955.
   PubMed Web of Science ®Google Scholar
• Rabadi MM, Kuo MC, Ghaly T, et al. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiology-Renal Physiol. 2012;302:F730–F741.
   PubMed Web of Science ®Google Scholar
• Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 1990;82:1113–1118.
   PubMed Web of Science ®Google Scholar
• Trouet A, Passioukov A, Van Derpoorten K, et al. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Res. 2001;61:2843–2846.
   PubMed Web of Science ®Google Scholar